RJFSA
SGMO

Raymond James Financial Services Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$10.2K Sell
11,833
-979
-8% -$717 ﹤0.01% 3420
2024
Q2 		$4.59K Sell
12,812
-537
-4% -$290 ﹤0.01% 3391
2024
Q1 		$8.95K Sell
13,349
-2,890
-18% -$2.1K ﹤0.01% 3372
2023
Q4 		$8.82K Sell
16,239
-9,393
-37% -$4.33K ﹤0.01% 3267
2023
Q3 		$15.4K Sell
25,632
-14,471
-36% -$15.5K ﹤0.01% 3204
2023
Q2 		$52.1K Sell
40,103
-34,204
-46% -$46.7K ﹤0.01% 3126
2023
Q1 		$131K Sell
74,307
-5,776
-7% -$16.5K ﹤0.01% 3014
2022
Q4 		$251K Sell
80,083
-4,243
-5% -$16.5K ﹤0.01% 2707
2022
Q3 		$413K Sell
84,326
-2,264
-3% -$11.6K ﹤0.01% 2363
2022
Q2 		$358K Sell
86,590
-6,202
-7% -$26.8K ﹤0.01% 2476
2022
Q1 		$539K Sell
92,792
-30,165
-25% -$179K ﹤0.01% 2334
2021
Q4 		$922K Sell
122,957
-110,266
-47% -$958K ﹤0.01% 2022
2021
Q3 		$2.1M Sell
233,223
-18,628
-7% -$184K ﹤0.01% 1463
2021
Q2 		$3.02M Buy
251,851
+9,267
+4% +$105K 0.01% 1244
2021
Q1 		$3.04M Buy
242,584
+41,743
+21% +$562K 0.01% 1161
2020
Q4 		$3.13M Buy
200,841
+140,683
+234% +$1.65M 0.01% 1047
2020
Q3 		$568K Sell
60,158
-3,290
-5% -$35.6K ﹤0.01% 1885
2020
Q2 		$568K Buy
63,448
+17,496
+38% +$162K ﹤0.01% 1834
2020
Q1 		$293K Buy
+45,952
New +$341K ﹤0.01% 1864
2019
Q4 		– Sell
-12,080
Closed -$109K – 2931
2019
Q3 		$109K Sell
12,080
-552
-4% -$6.19K ﹤0.01% 2620
2019
Q2 		$136K Buy
12,632
+602
+5% +$6.4K ﹤0.01% 2625
2019
Q1 		$115K Buy
12,030
+1,100
+10% +$11.2K ﹤0.01% 2623
2018
Q4 		$125K Sell
10,930
-20,665
-65% -$257K ﹤0.01% 2368
2018
Q3 		$536K Buy
31,595
+8,025
+34% +$122K ﹤0.01% 1853
2018
Q2 		$335K Buy
23,570
+6,250
+36% +$104K ﹤0.01% 2163
2018
Q1 		$329K Sell
17,320
-1,642
-9% -$35.1K ﹤0.01% 1980
2017
Q4 		$311K Buy
18,962
+4,300
+29% +$64K ﹤0.01% 2003
2017
Q3 		$220K Buy
+14,662
New +$162K ﹤0.01% 2212
2016
Q3 		– Sell
-12,783
Closed -$74K – 2377
2016
Q2 		$74K Buy
+12,783
New +$81.5K ﹤0.01% 2136

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Raymond James Financial Services Advisors's SGMO Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 7.6% in Q3 2024, selling an estimated $717 and leaving 11,833 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3420.

Raymond James Financial Services Advisors first reported a position in SGMO in Q2 2016 and has held it in 29 quarters since. The position peaked at $3.13M in Q4 2020. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Raymond James Financial Services Advisors held 11,833 shares of SANGAMO THERAPEUTICS INC worth $10.2K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 979 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $717.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3420 holding.
  • Raymond James Financial Services Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2016 and has held it in 29 quarters since.
  • Raymond James Financial Services Advisors's SANGAMO THERAPEUTICS INC position peaked at $3.13M in Q4 2020.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.